Atsuo Tahara
Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 41 publications
SGLT2 inhibitor ipragliflozin exerts antihyperglycemic effects via the blood glucose-dependent increase in urinary glucose excretion in type 2 diabetic mice.
Journal: European journal of pharmacology
Published: March 09, 2021
Effects of SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone on fluid retention in type 2 diabetic mice with NASH.
Journal: European journal of pharmacology
Published: February 03, 2021
Effects of neurokinin 3 receptor antagonist fezolinetant on hot flash-like symptoms in ovariectomized rats.
Journal: European journal of pharmacology
Published: January 09, 2021
Therapeutic Effects of SGLT2 Inhibitor Ipragliflozin and Metformin on NASH in Type 2 Diabetic Mice.
Journal: Endocrine research
Published: January 21, 2020
SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model.
Journal: Physiological reports
Published: November 30, 2019
Therapeutic effects of interleukin-1 receptor-associated kinase 4 inhibitor AS2444697 on diabetic nephropathy in type 2 diabetic mice.
Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: September 23, 2019
In Vitro Pharmacological Profile of Ipragliflozin, a Sodium Glucose Co-transporter 2 Inhibitor.
Journal: Biological & pharmaceutical bulletin
Published: March 05, 2019
Effects of the SGLT2 inhibitor ipragliflozin on food intake, appetite-regulating hormones, and arteriovenous differences in postprandial glucose levels in type 2 diabetic rats.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: March 05, 2018
Prevention of progression of diabetic nephropathy by the SGLT2 inhibitor ipragliflozin in uninephrectomized type 2 diabetic mice.
Journal: European journal of pharmacology
Published: January 10, 2018
Antidiabetic effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed diets containing different carbohydrate contents.
Journal: Life sciences
Published: October 19, 2017
Effects of the SGLT2 inhibitor ipragliflozin on various diabetic symptoms and progression of overt nephropathy in type 2 diabetic mice.
Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: September 05, 2017
Antidiabetic and antiobesity effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed sugar solution.
Journal: European journal of pharmacology
Published: March 21, 2017
Last Updated: 09/26/2026